Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities
Authors
Keywords
-
Journal
BIODRUGS
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2018-07-24
DOI
10.1007/s40259-018-0295-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Subcutaneous trastuzumab (Herceptin) versus intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer: A time, motion and cost assessment study in a lean operating day care oncology unit
- (2018) Wiebren A.A. Tjalma et al. European Journal of Obstetrics & Gynecology and Reproductive Biology
- Hematopoietic cells as site of first-pass catabolism after subcutaneous dosing and contributors to systemic clearance of a monoclonal antibody in mice
- (2018) Wolfgang F. Richter et al. mAbs
- High-concentration protein formulations: How high is high?
- (2017) Patrick Garidel et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- Drugs approved for the treatment of multiple sclerosis: review of their safety profile
- (2017) Fabiana Auricchio et al. Expert Opinion On Drug Safety
- Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin infusion in primary immunodeficiency diseases
- (2017) Richard L Wasserman Immunotherapy
- Update on the use of immunoglobulin in human disease: A review of evidence
- (2017) Elena E. Perez et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Perspectives on Subcutaneous Route of Administration as an Immunogenicity Risk Factor for Therapeutic Proteins
- (2017) Lora Hamuro et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Fixed Dosing of Monoclonal Antibodies in Oncology
- (2017) Jeroen J.M.A. Hendrikx et al. ONCOLOGIST
- Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial
- (2017) Andrew Davies et al. Lancet Haematology
- Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
- (2016) Saad Z. Usmani et al. BLOOD
- A Comparative Study of Intravenous Immunoglobulin and Subcutaneous Immunoglobulin in Adult Patients with Primary Immunodeficiency Diseases: A Systematic Review and Meta-Analysis
- (2016) Hosein Shabaninejad et al. Expert Review of Clinical Immunology
- Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency
- (2016) Richard L. Wasserman et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Understanding Subcutaneous Tissue Pressure for Engineering Injection Devices for Large-Volume Protein Delivery
- (2016) Diane V. Doughty et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer
- (2016) Erwin De Cock et al. Cancer Medicine
- Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries
- (2016) Erwin De Cock et al. PLoS One
- Tolerability of High-Volume Subcutaneous Injections of a Viscous Placebo Buffer: A Randomized, Crossover Study in Healthy Subjects
- (2015) Clapton Dias et al. AAPS PHARMSCITECH
- Herceptin® (trastuzumab) par voie sous-cutanée : une mini révolution ? Étude pharmaco-économique
- (2015) Vincent Lieutenant et al. BULLETIN DU CANCER
- The use of combinations of monoclonal antibodies in clinical oncology
- (2015) Linda M. Henricks et al. CANCER TREATMENT REVIEWS
- Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency in Routine Clinical Practice: The VISPO Prospective Multicenter Study
- (2015) Alessandra Vultaggio et al. CLINICAL DRUG INVESTIGATION
- Subcutaneous Trastuzumab for HER2-positive Breast Cancer – Evidence and Practical Experience in 7 German Centers
- (2015) C. Jackisch et al. GEBURTSHILFE UND FRAUENHEILKUNDE
- Human autoimmune diseases: a comprehensive update
- (2015) Lifeng Wang et al. JOURNAL OF INTERNAL MEDICINE
- Time And Motion Study For Rituximab Sc Vs Iv In Colombian Patients With Non-Hodgkin Lymphoma
- (2015) S.A. Saenz Ariza VALUE IN HEALTH
- Rituximab by subcutaneous route
- (2015) Philippe Solal-Celigny Expert Review of Hematology
- Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study
- (2014) X. Pivot et al. ANNALS OF ONCOLOGY
- Cost-minimization Analysis of IgPro20, a Subcutaneous Immunoglobulin, in Japanese Patients With Primary Immunodeficiency
- (2014) Ataru Igarashi et al. CLINICAL THERAPEUTICS
- Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study
- (2014) Andrew Davies et al. LANCET ONCOLOGY
- Time Savings With Transtuzumab Subcutaneous (SC) Injection Verse Trastuzumab Intravenous (IV) Infusion: A Time and Motion Study in 3 Russian Centers
- (2014) E. De Cock et al. VALUE IN HEALTH
- Cost-Minimization Analysis of Trastuzumab Intravenous Versus Trastuzumab Subcutaneous for the Treatment of Patients With HER2+ Early Breast Cancer And Metastatic Breast Cancer in Greece
- (2014) C. Mylonas et al. VALUE IN HEALTH
- Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom
- (2014) Simon Rule et al. JOURNAL OF MEDICAL ECONOMICS
- Immunogenicity of Subcutaneously Administered Therapeutic Proteins—a Mechanistic Perspective
- (2013) Anas M. Fathallah et al. AAPS Journal
- Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase
- (2013) O Shpilberg et al. BRITISH JOURNAL OF CANCER
- Subcutaneous Immunoglobulin for Primary and Secondary Immunodeficiencies: an Evidence-Based Review
- (2013) Jenny Lingman-Framme et al. DRUGS
- Pharmacokinetics and pharmacodynamics of single subcutaneous doses of tocilizumab administered with or without rHuPH20
- (2013) Peter N. Morcos et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study
- (2013) Xavier Pivot et al. LANCET ONCOLOGY
- Subcutaneous versus Intravenous Administration of Rituximab: Pharmacokinetics, CD20 Target Coverage and B-Cell Depletion in Cynomolgus Monkeys
- (2013) Cheng-Ping Mao et al. PLoS One
- Cost-Minimization of Mabthera Intravenous Versus Subcutaneous Administration
- (2013) P. Bax et al. VALUE IN HEALTH
- Hospital Resources Consumption Associated with Trastuzumab Treatment in Breast Cancer in Portugal
- (2013) S. Andrade et al. VALUE IN HEALTH
- Resource Consumption Evaluation Associated with Rituximab Administration in Portugal
- (2013) C. Pereira et al. VALUE IN HEALTH
- Phase III Study of the Efficacy and Safety of Subcutaneous Versus Intravenous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis
- (2013) Atsushi Ogata et al. ARTHRITIS CARE & RESEARCH
- Mechanistic Determinants of Biotherapeutics Absorption Following SC Administration
- (2012) Wolfgang F. Richter et al. AAPS Journal
- Home-Based Subcutaneous Immunoglobulin Versus Hospital-Based Intravenous Immunoglobulin in Treatment of Primary Antibody Deficiencies: Systematic Review and Meta Analysis
- (2012) Hassan Abolhassani et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Comparison of Subcutaneous and Intravenous Administration of Trastuzumab: A Phase I/Ib Trial in Healthy Male Volunteers and Patients With HER2-Positive Breast Cancer
- (2012) Chris Wynne et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial
- (2012) Gustavo Ismael et al. LANCET ONCOLOGY
- Subcutaneous abatacept versus intravenous abatacept: A phase IIIb noninferiority study in patients with an inadequate response to methotrexate
- (2011) M. C. Genovese et al. ARTHRITIS AND RHEUMATISM
- Improved Postprandial Glycemic Control in Patients with Type 2 Diabetes from Subcutaneous Injection of Insulin Lispro with Hyaluronidase
- (2011) Marcus Hompesch et al. Diabetes Technology & Therapeutics
- Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies
- (2010) J. Beauté et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Subcutaneous Immunoglobulin Therapy by Rapid Push is Preferred to Infusion by Pump: A Retrospective Analysis
- (2010) Ralph Shapiro JOURNAL OF CLINICAL IMMUNOLOGY
- Fixed Dosing Versus Body Size-Based Dosing of Monoclonal Antibodies in Adult Clinical Trials
- (2009) Diane D. Wang et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Subcutaneous Bioavailability of Golimumab at 3 Different Injection Sites in Healthy Subjects
- (2009) Zhenhua Xu et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Managing Premedications and the Risk for Reactions to Infusional Monoclonal Antibody Therapy
- (2008) C. H. Chung ONCOLOGIST
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started